About Vikram Pattanayak, MD, PhD
Vikram Pattanayak is an Assistant in Pathology at Massachusetts General Hospital and an Instructor in Pathology at Harvard Medical School. He has completed a residency in clinical pathology and fellowship in molecular genetic pathology and serves as the director of the Massachusetts General Hospital histocompatibility (HLA) laboratory.
In addition to his clinical interests, Dr. Pattanayak leads a subgroup of Keith Joung’s laboratory focused on the development of genome editing tools. During his M.D., Ph.D. thesis work with David Liu in the Harvard Chemistry department, he developed assays to define the specificities of designer endonucleases, including homing endonucleases, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and Cas9. As a member of the Joung lab, he engineered a variant of Cas9 (SpCas9-HF1) with minimal off-target effects.
Clinical Interests:
- Clinical Pathology
- Coagulation
Treats:
- Adult
Locations
Mass General Pathology
55 Fruit St.
Boston, MA 02114
Phone: 617-643-0800
Medical Education
- MD, Harvard Medical School*
- Residency, Massachusetts General Hospital
- Fellowship, Brigham and Women's Hospital
American Board Certifications
- Clinical Pathology, American Board of Pathology
Accepted Insurance Plans
- Aetna
- Beech Street
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Cigna
- Commonwealth Care Alliance
- Coventry
- Fallon Health
- Harvard Pilgrim Health Care
- Humana
- Mass General Brigham Health Plan
- MassHealth
- Medicaid ME
- Medicaid NH
- Medicaid RI
- Medicaid VT
- Medicare
- Medicare ACO
- Multiplan
- Senior Whole Health
- TriCare
- Tufts Health Plan
- United Health Care
- Wellpoint
- WellSense
- WellSense NH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Publications
-
Lareau, C.A., Clement, K., Hsu, J.Y., Pattanayak, V., Joung, J.K., Aryee, M.J., Pinello, L. Response to “Unexpected mutations after CRISPR-Cas9 editing in vivo.” Nature Methods. 15: 238, 2018.
Kleinstiver, B.P.*, Pattanayak, V.*, Prew, M.S., Tsai, S.Q., Nguyen, N.T., Zheng, Z., Joung, J.K. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 529: 490, 2016.
Pattanayak, V.*, Guilinger, J.P.*, Liu, D.R. Determining the specificities of TALENs, Cas9, and other genome-editing enzymes. Methods in Enzymology. 546: 47, 2014.
Guilinger, J.P., Pattanayak, V., Reyon, D., Tsai, S.Q., Sander, J.D., Joung, J.K., Liu, D.R. Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity. Nature Methods. 11: 429, 2014.
Pattanayak, V., Lin, S., Guilinger, J.P., Ma, E., Doudna, J.A., Liu, D.R. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nature Biotechnology. 31: 839-843, 2013.
Pattanayak, V., Ramirez, C.L., Joung, J.K., Liu, D.R. Revealing off-target cleavage specificities of zinc finger nucleases by in vitro selection. Nature Methods. 9: 765-770, 2011.
Doyon, J.B., Pattanayak, V., Meyer, C.B., Liu, D.R. Directed evolution and substrate specificity profile of homing endonuclease I-SceI. J. Am. Chem. Soc. 128: 2477-84, 2006.